Benzylidene 2-Aminoimidazolones Derivatives: Synthesis and <i>in Vitro</i> Evaluation of Anti-tumor Carcinoma Activity
作者:Yong Ling、Zhi-Qiang Wang、You-An Xiao、Chenyu Zhu、Liucen Shen、Xue-Min Wang、Yi Hui、Xin-Yang Wang
DOI:10.1248/cpb.c13-00340
日期:——
A series of benzylidene 2-aminoimidazolones derivatives were synthesized. Most compounds displayed strong inhibitory activity on the proliferation of human HepG2 cells in vitro. The active compounds were further evaluated by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay against five human cancer cell lines in vitro. Compound 2b exhibited the strongest antitumor activities with IC50 values ranging from 12.87–17.10 µM which were nearly 1–3.5 fold less than that of 5-FU (IC50=18.39–56.12 µM) in vitro. Furthermore, compound 2b could induce SMMC-7721 cell apoptosis in a dose-dependent manner. Therefore, our novel findings may provide a new framework for the design of new benzylidene 2-aminoimidazolones derivatives for the treatment of cancer.
合成了一系列苯亚甲基 2-氨基咪唑啉酮衍生物。大多数化合物对体外人 HepG2 细胞的增殖具有很强的抑制活性。通过 3-(4,5-二甲基噻唑-2-基)-2,5-二苯基溴化四氮唑(MTT)试验,进一步评估了这些活性化合物对五种人类癌症细胞株的体外活性。化合物 2b 的抗肿瘤活性最强,体外 IC50 值为 12.87-17.10 µM ,比 5-FU (IC50=18.39-56.12 µM )低近 1-3.5 倍。此外,化合物 2b 能以剂量依赖的方式诱导 SMMC-7721 细胞凋亡。因此,我们的新发现可能为设计新的苯亚甲基 2-氨基咪唑啉酮衍生物治疗癌症提供了一个新的框架。